Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on Inaticabtagene Autoleucel (Inati-cel; CNCT19) Injection for Adolescents and Adults With B-Cell Acute Lymphoblastic Leukemia in First Complete Remission (CR1)

NCT06777264 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT06777264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06777264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on Inaticabtagene Autoleucel (Inati-cel; CNCT19) Injection for Adolescents and Adults With B-Cell Acute Lymphoblastic Leukemia in First Complete Remission (CR1)
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 15, 2025
Completion date
January 15, 2027
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, b cell all